Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab

被引：0

作者：

Damassi, Alessandra ^{[1
]}

Cremante, Malvina ^{[1
]}

Signori, Alessio ^{[2
]}

Rebuzzi, Sara Elena ^{[3
,4
]}

Malgeri, Andrea ^{[5
]}

Napoli, Marilena Di ^{[6
]}

Caffo, Orazio ^{[7
]}

Vignani, Francesca ^{[8
]}

Cavo, Alessia ^{[9
]}

Roviello, Giandomenico ^{[10
]}

Prati, Veronica ^{[11
]}

Tudini, Marianna ^{[12
]}

Atzori, Francesco ^{[13
]}

Messina, Marco ^{[14
]}

Morelli, Franco ^{[15
]}

Prati, Giuseppe ^{[16
]}

Nole, Franco ^{[17
]}

Catalano, Fabio ^{[1
]}

Murianni, Veronica ^{[1
]}

Rescigno, Pasquale ^{[18
,19
]}

Banna, Giuseppe Luigi ^{[20
,21
]}

Fornarini, Giuseppe ^{[1
]}

Buti, Sebastiano ^{[22
,23
]}

机构：

[1] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, I-16132 Genoa, Italy

[2] Univ Genoa, Sect Biostat, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy

[3] Osped San Paolo, Med Oncol Unit, I-17100 Savona, Italy

[4] Univ Genoa, Dept Internal Md & Med Specialties DiMI, I-16132 Genoa, Italy

[5] Univ Campus Biomed Roma, Dept Med Oncol, I-00128 Rome, Italy

[6] Ist Ricovero & Cura Carattere Sci IRCCS Fdn G Pasc, Ist Ricovero & Cura Carattere Sci, Dept Urol & Gynecol, Ist Nazl Tumori, I-80131 Naples, Italy

[7] Osped Santa Chiara APSS, Dept Med Oncol, I-38100 Trento, Italy

[8] Ordine Mauriziano Hosp, Div Med Oncol, I-10128 Turin, Italy

[9] Villa Scassi Hosp, Oncol Unit, I-10128 Genoa, Italy

[10] Univ Firenze, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, I-50139 Florence, Italy

[11] Osped Michele & Pietro Ferrero, Dept Gynecol Oncol, Azienda Sanit Locale CN2, I-12060 Verduno, Italy

[12] St Salvatore Hosp, Med Oncol, I-67100 Laquila, Italy

[13] Osped Sirai Carbonia, SSD Oncol Med, ASLSulcis, I-09013 Sirai, Italy

[14] Osped Civ ARNAS, Med Oncol, I-90127 Palermo, Italy

[15] IRCCS Casa Sollievo Sofferenza, Oncol Dept, Foggia, Italy

[16] IRCCS AUSL Reggio Emilia, Dept Oncol & Advances Technol, Reggio Emilia, Italy

[17] European Inst Oncol IRCCS, Med Oncol Div Urogenital Head Neck Tumors, IEO, I-20141 Milan, Italy

[18] Newcastle Univ, Translat & Clin Res Inst, Ctr Canc, Newcastle Upon Tyne NE7 7DN, England

[19] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, Italy

[20] Portsmouth Hosp Univ NHS Trust, Portsmouth PO6 3LY, England

[21] Univ Portsmouth, Fac Sci & Hlth, Sch Pharm & Biomed Sci, Portsmouth PO12UP, England

[22] Univ Hosp Parma, Med Oncol Unit, I-43126 Parma, Italy

[23] Univ Parma, Dept Med & Surg, I-43121 Parma, Italy

来源：

IMMUNOTHERAPY | 2024年 / 16卷 / 18-19期

关键词：

IMDC score; meet-URO score; metastatic renal cell carcinoma; nivolumab; treatment sequence; tyrosine kinase inhibitor; SUNITINIB;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received >= second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.

引用

页码：1095 / 1103

页数：9

共 35 条

[1] Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
Amaro, Filipa
Pisoeiro, Carolina
Valente, Maria Joao
Bastos, Maria de Lourdes
de Pinho, Paula Guedes
Carvalho, Marcia
Pinto, Joana
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
[2] Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Amin, Asim
Plimack, Elizabeth R.
Ernstoff, Marc S.
Lewis, Lionel D.
Bauer, Todd M.
McDermott, David F.
Carducci, Michael
Kollmannsberger, Christian
Rini, Brian I.
Heng, Daniel Y. C.
Knox, Jennifer
Voss, Martin H.
Spratlin, Jennifer
Berghorn, Elmer
Yang, Lingfeng
Hammers, Hans J.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[3] Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
Buti, Sebastiano
Donini, Maddalena
Bersanelli, Melissa
Gattara, Alessia
Leonardi, Francesco
Passalacqua, Rodolfo
[J]. DRUGS IN R&D, 2017, 17 (04) : 585 - 596
[4] A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Costello, Brian A.
Bhavsar, Nrupen A.
Zakharia, Yousef
Pal, Sumanta K.
Vaishampayan, Ulka
Jim, Heather
Fishman, Mayer N.
Molina, Ana M.
Kyriakopoulos, Christos E.
Tsao, Che-Kai
Appleman, Leonard J.
Gartrell, Benjamin A.
Hussain, Arif
Stadler, Walter M.
Agarwal, Neeraj
Pachynski, Russell K.
Hutson, Thomas E.
Hammers, Hans J.
Ryan, Christopher W.
Mardekian, Jack
Borham, Azah
George, Daniel J.
Harrison, Michael R.
[J]. CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 1 - 10
[5] Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma
de Velasco, Guillermo
Bex, Axel
Albiges, Laurence
Powles, Thomas
Rini, Brian I.
Motzer, Robert J.
Heng, Daniel Y. C.
Escudier, Bernard
[J]. EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (05): : 505 - 514
[6] A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Deng, Huan
Li, Meng
Wu, Qian
Wang, Li
Hong, Zhengdong
Yi, Fengming
Wei, Yiping
Zhang, Wenxiong
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
[8] Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments
Fumarola, Claudia
La Monica, Silvia
Bonelli, Mara
Zoppi, Silvia
Alfieri, Roberta
Galetti, Maricla
Gnetti, Letizia
Campanini, Nicoletta
Pozzi, Giulia
Cavazzoni, Andrea
Mazzaschi, Giulia
Silini, Enrico Maria
Buti, Sebastiano
Petronini, Pier Giorgio
[J]. BIOCHEMICAL PHARMACOLOGY, 2024, 226
[9] The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
Garje, Rohan
An, Josiah
Greco, Austin
Vaddepally, Raju Kumar
Zakharia, Yousef
[J]. CANCERS, 2020, 12 (01)
[10] External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Heng, Daniel Y. C.
Xie, Wanling
Regan, Meredith M.
Harshman, Lauren C.
Bjarnason, Georg A.
Vaishampayan, Ulka N.
Mackenzie, Mary
Wood, Lori
Donskov, Frede
Tan, Min-Han
Rha, Sun-Young
Agarwal, Neeraj
Kollmannsberger, Christian
Rini, Brian I.
Choueiri, Toni K.
[J]. LANCET ONCOLOGY, 2013, 14 (02) : 141 - 148

← 1 2 3 4 →